BioMarin Pharmaceutical (Nasdaq:BMRN) saw its share price dip 3.5% in mid-day trading to $88.30 after announcing a reorganization. The company said it would cut 4% of its workforce, or approximately 120 positions, to save cash. In a press release, BioMarin cited the potential launch of Roctavian as one of the reasons beyond the layoff. The…

The pandemic has heightened interest in COVID-19 therapies, sometimes stealing attention from other pharmaceutical breakthroughs. But the pandemic has also served as a reminder that investment in new drugs can pay dividends while leading to a greater societal appreciation for the industry. A 2019 study published in International Health concluded that pharmaceuticals that have launched…